Form 4: Ginkgo Bioworks Director Harry Sloan Reports Equity Transactions, Including RSU Vesting and New Option Grant

Ginkgo Bioworks Holdings, Inc. Director Harry Sloan reported the vesting of restricted stock units and the grant of new stock options, increasing his direct ownership of Class A Common Stock.

Summary

• Director Harry Sloan acquired 10,822 shares of Ginkgo Bioworks Class A Common Stock on June 11, 2025, through the vesting of restricted stock units (RSUs).
• These RSUs, granted on June 13, 2024, vested in full on June 11, 2025, in accordance with the Issuer's Non-Employee Director Compensation Program, subject to his continued service.
• Following this transaction, Mr. Sloan directly beneficially owns 271,418 shares of Class A Common Stock.
• On June 12, 2025, Mr. Sloan was granted 34,375 stock options with an exercise price of $9.29 per share.
• These new options were granted under the Issuer's Amended and Restated Non-Employee Director Compensation Program, which became effective on June 12, 2025.
• The stock options will vest in substantially equal installments on each of the first three anniversaries of the grant date (June 12, 2025), provided Mr. Sloan continues his service as a Non-Employee Director.

Sentiment

Score: 6

Explanation: The document reports routine director compensation transactions. The increase in direct share ownership and the grant of new options are mildly positive as they align director interests with shareholders, but the filing itself is not indicative of significant operational or financial news.

Positives

• Director Harry Sloan increased his direct beneficial ownership of Class A Common Stock by 10,822 shares through RSU vesting, aligning his interests further with shareholders.
• The grant of 34,375 new stock options indicates continued commitment and incentivization for the director's long-term service to the company.

Risks

• The vesting of the newly granted stock options is subject to the Non-Employee Director continuing in service through each vesting date, posing a risk to the director's full equity realization if service ceases.

Future Outlook

The newly granted stock options will vest in substantially equal installments over the next three years, contingent on Director Harry Sloan's continued service as a Non-Employee Director.

Industry Context

This filing is a routine disclosure of insider equity transactions, common across all publicly traded companies, and does not provide specific insights into broader industry trends or competitive landscape beyond the company's internal compensation practices.

Comparison to Industry Standards

• The structure of director compensation, involving a mix of RSU vesting and stock option grants, is a common practice in the biotechnology and technology sectors, aligning director incentives with long-term shareholder value.
• The vesting schedule for stock options over three years is a standard approach to encourage long-term commitment and retention of non-employee directors, comparable to practices at companies like Moderna (MRNA) or Illumina (ILMN) in the life sciences space.

Corporate Governance

Stakeholder Impact

• Shareholders: The vesting of RSUs and grant of stock options to a director can align management interests with shareholder value, but also represent potential future dilution from option exercises.
• Employees: Not directly impacted by this specific director transaction, but the compensation program reflects broader corporate governance on equity incentives.

Next Steps

• The stock options granted on June 12, 2025, will vest in substantially equal installments on the first three anniversaries of the grant date.

Key Dates

Keywords

Ginkgo Bioworks Holdings Inc, DNA, Harry Sloan, SEC Form 4, Insider Trading, Restricted Stock Units, Stock Options, Director Compensation, Equity Grant, Beneficial Ownership